Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.

Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells.
复制标题

DOI:
10.1126/science.1191536
复制
发表时间:
2010-09-10
期刊:
Science (New York, N.Y.)
影响因子:
--
通讯作者:
Cooke MP
Cooke MP
中科院分区:
其他
文献类型:
--
作者:
Boitano AE;Wang J;Romeo R;Bouchez LC;Parker AE;Sutton SE;Walker JR;Flaveny CA;Perdew GH;Denison MS;Schultz PG;Cooke MP

文献摘要

参考文献

被引文献

相似文献

尽管临床实践已超过40年,但造血干细胞(HSC)移植的使用仍然受到离体扩增这些细胞的能力的限制。用原代人HSC进行的无偏筛选鉴定了嘌呤衍生物StemRegenin 1(SR1),其促进CD 34+细胞的离体扩增。用SR1培养HSC导致表达CD34的细胞增加了50倍,保留移植免疫缺陷小鼠能力的细胞增加了17倍。机制研究表明,SR1通过拮抗芳烃受体(AhR)发挥作用。鉴定SR1和AhR调节作为诱导离体HSC扩增的手段应有助于HSC治疗的临床应用。
Although practiced clinically for over 40 years, the use of hematopoietic stem cell (HSC) transplants remains limited by the ability to expand these cells ex vivo. An unbiased screen with primary human HSC identified a purine derivative, StemRegenin 1 (SR1), that promotes the ex vivo expansion of CD34+ cells. Culture of HSC with SR1 led to a fifty-fold increase in cells expressing CD34, and a 17-fold increase in cells that retain the ability to engraft immunodeficient mice. Mechanistic studies show that SR1 acts by antagonizing the aryl hydrocarbon receptor (AhR). The identification of SR1 and AhR modulation as a means to induce ex vivo HSC expansion should facilitate the clinical use of HSC therapy.
DOI: 10.1089/scd.2007.9995
发表时间: 2007-06-01
影响因子: 4
作者:
Campbell, Timothy B.;Hangoc, Giao;Broxmeyer, Hal E.
通讯作者: Broxmeyer, Hal E.
DOI: 10.1124/mol.109.054825
发表时间: 2009-06-01
影响因子: 3.6
作者:
Flaveny, Colin A.;Murray, Iain A.;Perdew, Gary H.
通讯作者: Perdew, Gary H.
DOI: 10.1016/j.reprotox.2007.08.002
发表时间: 2007-11-01
影响因子: 3.3
作者:
Jang, Ja Young;Shin, Sunhee;Nahm, Sang-Seop
通讯作者: Nahm, Sang-Seop
DOI: 10.2307/1535560
发表时间: 1908-06-01
影响因子: 1.6
作者:
Smith, BG
通讯作者: Smith, BG
DOI: 10.1021/ja0170302
发表时间: 2002-02-27
影响因子: 15
作者:
Ding, S;Gray, NS;Schultz, PG
通讯作者: Schultz, PG